The study conducted in NSCLC illuminates the intricate interplay between c-MET inhibition and immune evasion, providing a compelling rationale for the combined treatment approach involving c-MET inhibitors and immune checkpoint blockade (9). This evidence concerns the gene MET and non-small cell lung carcinoma.